09:35 AM EST - Oncolytics Biotech Inc : Announces recent operational highlights and financial results for the first quarter ended March 31, 2024. Pelareorep advancing to registration-enabling studies. Preparations are underway for Type C meeting with the FDA to establish registrational pathway in HR+/HER2- metastatic breast cancer. Overall survival data from BRACELET-1 breast cancer study is expected in H2 2024. A cash position of $29.6 million provides runway through critical milestones into 2025, Oncolytics Biotech Inc
shares T.ONC are trading up $0.07 at $1.69.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONC%3ACA&qmodStoryID=5103632937125659
